Transplantation of umbilical cord mesenchymal stem cells combined with haploidentical hematopoietic stem cells for 36 patients with refractory/relapsed myeloid leukemia.
10.7534/j.issn.1009-2137.2014.04.031
- Author:
Ya-Mei WU
1
;
Yong-Bin CAO
1
;
Xiao-Hong LI
1
;
Li-Xin XU
1
;
Zhou-Yang LIU
1
;
Bei LIU
1
;
Bei YAN
1
;
Xue-Liang YANG
1
;
Song-Wei LI
1
;
Wan-Ming DA
2
;
Chun-Ji GAO
2
;
Xiao-Xiong WU
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
2. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
3. Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China. E-mail: xiongwuxiao@sohu.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Cord Blood Stem Cell Transplantation;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid;
therapy;
Male;
Mesenchymal Stem Cell Transplantation;
Middle Aged;
Retrospective Studies;
Transplantation, Homologous;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(4):1053-1057
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to analyse the clinical efficacy of transplantation of umbilical cord mesenchymal stem cells (UC-MSC) combined with haploidentical hematopoietic stem cells (haplo-HSCT) for patients with refractory/relapsed myeloid leukemia. The clinical data of 36 patients received transplantation of UC-MSC combined with haplo-HSCT from January 2007 to June 2013 were summarized retrospectively, the engraftment, GVHD and 2 years-overall survival (OS) were analysed. The results showed that the median times of neutrophil count>0.50×10(9)/L and platelet count>20×10(9)/L were 12.0 days and 14.0 days, respectively. Grade III to IV aGVHD occurred in 5 out of 36 patients (13.8%). cGVHD occurred in 12 out of 32 patients (37.5%) and extensive cGVHD occurred in 2 patients. Additionally, only 3 patients (8.3%) experienced relapse. The 2-year OS rate of patients was 76.9%. It is concluded that the transplantation of UC-MSC combined with haplo-HSCT has good therapeutic efficacy for patients with refractory/relapsed myeloid leukemia, and may be served as a therapeutic method especially for patients with high risk and without well matched donor.
